A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our Company We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Regulatory RNAs (“regRNAs”), play a central role in the regulation of every protein-coding gene by contributing to gene activation and suppression. Our approach is designed to amplify messenger RNA (“mRNA”), expression by harnessing the power of regRNAs that form localized complexes with transcription factors and regulate gene expression. Our proprietary RNA Actuating Platform, or RAP Platform, allows us to rapidly and systematically identify and characterize the active regulatory elements controlling every expressed gene and tens of thousands of druggable enhancer and promoter regRNA sequences that control protein-coding genes.
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 3.8M | - | 350K |
| Net Income | -53M | -52M | - |
| EPS | $63.68 | $-11.04 | $-124.80 |
| Free Cash Flow | -48M | -46M | -45M |
| ROIC | -49.2% | -81.9% | - |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.00 | -0.00 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -54M | -53M | -52M |
| Operating Margin | -1415.4% | - | -14822.6% |
| ROE | -91.0% | -82.0% | - |
| Shares Outstanding | 47M | 20M | 20M |
| Metric | 2023 | ||
|---|---|---|---|
| Income Statement | |||
| Revenue | 350K | N/A | 3.8M |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -52M | -53M | -54M |
| Op. Margin | -14822.6% | N/A | -1415.4% |
| Net Income | N/A | -52M | -53M |
| Net Margin | N/A | N/A | -1404.5% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | N/A | -81.9% | -49.2% |
| ROE | N/A | -82.0% | -91.0% |
| ROA | N/A | -77.7% | -61.8% |
| Cash Flow | |||
| Op. Cash Flow | -44M | -46M | -47M |
| Free Cash Flow | -45M | -46M | -48M |
| Owner Earnings | -49M | -51M | -53M |
| CapEx | 678K | 441K | 0 |
| Maint. CapEx | 1.7M | 1.7M | 1.7M |
| Growth CapEx | 0 | 0 | 0 |
| D&A | 1.7M | 1.7M | 1.7M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.9M | 4.0M | 4.0M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | -38M | -64M | -75M |
| Cash & Equiv. | N/A | N/A | 75M |
| Long-Term Debt | 148K | 70K | 70K |
| Debt/Equity | -0.00 | 0.00 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | -124M | 63M | 59M |
| Total Assets | 55M | 78M | 86M |
| Total Liabilities | 17M | 15M | 28M |
| Intangibles | N/A | N/A | N/A |
| Retained Earnings | -160M | -212M | -212M |
| Working Capital | 32M | 57M | 57M |
| Current Assets | 40M | 66M | 66M |
| Current Liabilities | 7.8M | 9.6M | 9.6M |
| Per Share Data | |||
| EPS | -124.80 | -11.04 | 63.68 |
| Owner EPS | -2.42 | -2.54 | -1.13 |
| Book Value | -6.14 | 3.13 | 1.25 |
| Cash Flow/Share | -2.19 | -2.26 | -1.10 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 20.2M | 20.2M | 46.9M |
| Valuation | |||
| P/E Ratio | N/A | N/A | 0.1 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | 1.7 | 3.6 |
| Price/Sales | N/A | N/A | 55.7 |
| FCF Yield | N/A | -42.0% | -22.5% |
| Market Cap | N/A | 109M | 212M |
| Avg. Price | N/A | 8.32 | 4.52 |
| Year-End Price | N/A | 5.43 | 4.52 |
Camp4 Therapeutics Corp passes 1 of 9 quality checks, indicating weak fundamentals.
Camp4 Therapeutics Corp trades at 0.1x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range.
Camp4 Therapeutics Corp (CAMP) has a current P/E ratio of 0.1, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
Camp4 Therapeutics Corp (CAMP) has a 5-year average return on invested capital (ROIC) of -81.9%. This is below average and may indicate limited pricing power.
Camp4 Therapeutics Corp (CAMP) has a market capitalization of $212M. It is classified as a small-cap stock.
Camp4 Therapeutics Corp (CAMP) does not currently pay a regular dividend.
Based on historical P/E analysis, Camp4 Therapeutics Corp (CAMP) appears cheap. The current P/E of 0.1 is 100% below its historical median of 15.0.
Camp4 Therapeutics Corp (CAMP) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Camp4 Therapeutics Corp (CAMP) generated $-46 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Camp4 Therapeutics Corp (CAMP) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Camp4 Therapeutics Corp (CAMP) reported earnings per share (EPS) of $-11.04 in its most recent fiscal year.
Camp4 Therapeutics Corp (CAMP) has a return on equity (ROE) of -82.0%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Camp4 Therapeutics Corp (CAMP), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Camp4 Therapeutics Corp (CAMP) has a book value per share of $3.13, based on its most recent annual SEC filing.